Macrogen Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
48,078
54,130
79,534
91,113
101,793
Cost of Goods Sold (COGS) incl. D&A
27,785
33,489
54,270
62,575
69,594
Gross Income
20,293
20,640
25,263
28,538
32,199
SG&A Expense
16,725
18,040
20,700
25,011
28,558
EBIT
3,568
2,601
4,167
3,141
3,220
Unusual Expense
811
78
2,002
435
445
Non Operating Income/Expense
4,636
542
5,718
3,157
10,616
Interest Expense
1,557
338
835
1,948
2,164
Pretax Income
6,836
3,302
7,968
5,865
12,009
Income Tax
364
109
951
1,253
4,450
Equity in Affiliates
19
160
1,163
185
-
Consolidated Net Income
6,453
3,033
10,083
4,427
7,559
Net Income
6,426
2,989
10,172
4,301
7,813
Net Income After Extraordinaries
6,426
2,989
10,172
4,301
7,813
Net Income Available to Common
6,426
2,989
10,172
4,301
7,813
EPS (Basic)
746.00
338.67
1,150.00
487.00
860.00
Basic Shares Outstanding
9
9
9
9
9
EPS (Diluted)
728.58
328.05
1,112.33
472.79
858.67
Diluted Shares Outstanding
9
9
9
9
9
EBITDA
8,832
9,909
13,259
14,380
14,457
Other Operating Expense
-
-
396
385
420
Non-Operating Interest Income
1,001
575
920
1,080
781
Minority Interest Expense
27
44
89
126
254

About Macrogen

View Profile
Address
10/F, World Meridian Venture Center
Seoul SL 08511
Korea, Republic Of
Employees -
Website http://www.macrogen.co.kr
Updated 09/14/2018
Macrogen, Inc. engages in the provision genetic research and biotechnology services. It services include genome sequencing, oligonucleotide, microarray, genetically engineered mouse, and clinical sequencing. The company was founded on June 5, 1997 and is headquartered in Seoul, South Korea.